Min Li, SciNeuro CEO
Once a GSK hopeful for heart disease, an inhibitor class makes a comeback in Alzheimer's deal
In 2014, GSK faced two back-to-back Phase III flops for the heart drug darapladib it once hoped would be a blockbuster. Those failures effectively dimmed the light on the entire group of fatty acid enzyme inhibitors from which darapladib hailed.
Now, some eight years later, the pharma giant is shipping off a series of those Lp-PLA2 inhibitors to SciNeuro, a startup built by GSK’s former R&D head in Shanghai, Min Li — though the deal does not include darapladib. But SciNeuro is taking Lp-PLA2 inhibitors in a very different direction: Alzheimer’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
